Terran Biosciences, the NY-based biotech platform that develops transformational therapeutics announced the publication of four international PCT patent applications covering novel compounds and potentially improved versions of the empathogens methylone (also called bk-MDMA or MDMC), ethylone, MDEA (aka MDE), MDAI, and MBDB.
The company works towards developing distinct therapeutic options tailored to specific patient needs, so that for instance patients with the most severe forms of PTSD may benefit from the most powerful empathogens such as MDMA and MDEA, while patients with milder forms of PTSD, anxiety or depression may benefit from medicines such as MDAI or MBDB. Empathogens are compounds that increase feelings of empathy.
While MDMA has been the most studied one, related compound methylone invented by renowned chemists Alexander Shulgin and Peyton Jacob III has been described as efficacious in treating PTSD through inducing a milder sensorial experience than the former.
Results on which the patent applications are based:
-
Racemic methylone did not follow a classic dose-dependent pattern but …